Jianfeng Pharmaceutical has made clear its key work in the new year.
Release time:
2023-02-22
2022 held on February 19 , Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, and Huang Jinlongfen, deputy general manager of the group company and general manager of the pharmaceutical company, made arrangements for the key work of pharmaceutical company 2023 and put forward specific requirements. 2023 With the adjustment of the national epidemic control policy, the domestic into the post-epidemic period, the pharmaceutical company will focus on
"to reduce the first, innovation-oriented, marketing-led, standardized and efficient " work policy, and solidly promote the production and operation management work. In terms of market expansion, the pharmaceutical industry should optimize management and business teams, strengthen process control, purify the market environment, cultivate benchmark markets, and expand Internet marketing; pharmaceutical business should give full play to regional advantages, make full use of government resources, and expand and strengthen subdivision areas; pharmaceutical retail should comply with changes in the market and customer needs, and seek breakthroughs in business philosophy and business ideas; natural products companies continue to give full play to their advantages in quality, technology, information and brand, expand new areas of the market, focus on the development of the domestic ordinary food market, maintain a steady growth in sales volume, and increase the added value of products; Shanghai Beika should find out the changing law of the pesticide market, expand the sales of pesticide products at the best price, and strive to strengthen cooperation with pharmaceutical R & D and production enterprises to achieve differentiated sales.
In terms of new drug development, continue to strengthen communication and coordination between various levels and departments; strengthen communication with drug review and approval departments to improve the speed and success rate of new drug approval; strengthen in-depth cooperation with
CROCompany to improve new drug research and development capabilities; scientifically formulate product development plans, further clarify the responsibilities of development, production and quality departments, and accelerate the speed of new drug research and development; continue to carry out technical research, continuously optimize process parameters, improve yield, continue to introduce varieties of raw material preparation integration, stimulate the potential of API bases and preparation internationalization projects, increase the introduction and development efforts, enrich the enterprise product line. In terms of the construction and technological transformation of the project, make preparations for the international project to meet the
FDAon-site inspection. Complete all kinds of acceptance of various construction projects and relevant approval work before putting them into production, and reach the production standard as soon as possible. Increase foreign cooperation, give full play to the advantages of production capacity and increase revenue; Continue to promote various informatization work and continuously improve the informatization and intelligence level of enterprises. In terms of cost control, further optimize the synthesis process of bulk drugs and improve the yield; Further strengthen the control of the preparation production process; Strengthen the coordination of production and marketing, optimize the production organization mode, and reasonably arrange the production cycle; Speed up the work process of photovoltaic power generation projects; Reasonable deployment of personnel to improve work efficiency; Reduce procurement costs and ensure stable supply by increasing suppliers of raw and auxiliary packaging materials.
In terms of internal control management, we will continue to improve the internal control system of the enterprise, improve the operability of the internal control system, and increase the intensity of system assessment; continue to strengthen tax planning and communicate with the tax authorities to keep abreast of policy developments and reduce the risk of tax inspection.
In terms of safety and environmental protection, take the implementation of the new safety production law as an opportunity to increase the publicity and education of laws and regulations; standardize the development of various production and business activities to ensure the safety of personnel and property. In terms of product quality,
, further strengthen self-inspection of
GMPand GSP , discover potential quality hazards in time, and implement responsibilities; Taking the opportunity of international projects receiving US FDA certification, strengthen staff education and training, and improve professional skills and professional work ability; Attach great importance to pharmacovigilance and adverse reaction monitoring; Strengthen the construction of quality management system, further standardize quality management and quality control behavior. In terms of team building, we should attach importance to the introduction, training and use of talents, so as to provide more platforms for the growth of talents; select young cadres to enrich the management teams at all levels, enhance the vitality of the team, and create a well-trained, dedicated staff team and a United, pragmatic, responsible and capable management team, so as to meet the needs of sustainable development of enterprises. (Reporter
Ni Yingzhen)
More information
In the eastern corner of the production area of Jianfeng Health Technology Company, there is a very inconspicuous building. From below, only a few pipes of uneven thickness can be seen on the top and the slogan "Focus on Environmental Protection and Promote Sustainable Development" with red letters on the yellow background on the stainless steel guardrail. Walking up, you can only see several closed pools and a small room with stacks of documents, test tubes, glass bottles and other testing tools on the table. This is the peak and healthy sewage treatment station. The production sewage of the whole factory area is concentrated here. After adjustment (PH adjustment), pre-acidification, anaerobic, anoxic, aerobic (aeration), precipitation and other links, it is discharged into the pipe network after reaching the special discharge standard. Yin Zhiwu, executive deputy general manager of Jianfeng Health, said that because the sewage treatment station in Wucheng District has not yet been built, Jianfeng Health has not yet been able to achieve pipe discharge, and the relevant national laws have strict requirements on the discharge of water pollutants from the extraction pharmaceutical industry. Sewage discharge must reach a special discharge limit, that is, chemical oxygen demand (COD) must be less than 50 mg/L. Enterprise development and environmental protection are both the concept of peak health since its establishment. In March this year, on the basis of the original environmental protection facilities, Jianfeng Health carried out technical renovation of waste gas collection and treatment facilities, and at the same time installed a sealing cover on the sewage treatment station to realize the closed collection of waste gas. Since the trial operation of this facility in mid-May, the overall effect has been obvious. The original treatment tank would emit an unpleasant smell during work, but now the smell has been significantly reduced. Compared with the young enterprise of peak health, the relatively "older" peak pharmaceutical has more experience in sewage treatment and environmental protection. Akihama
2020
07-31
2016 Annual General Meeting of Shareholders
News from our newspaper On May 19, the on-site meeting of Jianfeng Group's 2016 Annual General Meeting of Shareholders was held in Conference Room 314 of Jianfeng Building to deliberate and pass the "2016 Annual Report on the Work of the Board of Directors" and other proposals. The meeting was convened by the board of directors of Jianfeng Group and chaired by Chairman Jiang Xiaomeng. A total of 6 shareholders and proxies attended the meeting, and the total number of voting shares held by them was 55,604,815, accounting for 16.16 of the total voting shares of the company. Some directors, supervisors and secretary of the board of directors of the company attended the meeting, and some senior managers attended the meeting as nonvoting delegates. The meeting was held and voted on by a combination of on-site voting and online voting, it deliberated and passed nine proposals, including the 2016 Work Report of the Board of Directors, the 2016 Work Report of the Board of Supervisors, the 2016 Financial Final Accounts Report, the 2016 Profit Distribution Proposal, the Proposal to Hire the Company's 2017 Audit Institution, the Proposal to Provide Guarantee to Holding Subsidiaries, the 2016 Annual Report and its Summary, the Election of Mr. Huang Sujian as Director of the Company and the Election of Mr. Chen Tianci as Supervisor of the Company. (Zhou Hengbin)
2020
07-31
2016 Annual General Meeting of Shareholders
News from our newspaper On May 19, the on-site meeting of Jianfeng Group's 2016 Annual General Meeting of Shareholders was held in Conference Room 314 of Jianfeng Building to deliberate and pass the "2016 Annual Report on the Work of the Board of Directors" and other proposals. The meeting was convened by the board of directors of Jianfeng Group and chaired by Chairman Jiang Xiaomeng. A total of 6 shareholders and proxies attended the meeting, and the total number of voting shares held by them was 55,604,815, accounting for 16.16 of the total voting shares of the company. Some directors, supervisors and secretary of the board of directors of the company attended the meeting, and some senior managers attended the meeting as nonvoting delegates. The meeting was held and voted on by a combination of on-site voting and online voting, it deliberated and passed nine proposals, including the 2016 Work Report of the Board of Directors, the 2016 Work Report of the Board of Supervisors, the 2016 Financial Final Accounts Report, the 2016 Profit Distribution Proposal, the Proposal to Hire the Company's 2017 Audit Institution, the Proposal to Provide Guarantee to Holding Subsidiaries, the 2016 Annual Report and its Summary, the Election of Mr. Huang Sujian as Director of the Company and the Election of Mr. Chen Tianci as Supervisor of the Company. (Zhou Hengbin)
2020
07-31
2016 Annual General Meeting of Shareholders
News from our newspaper On May 19, the on-site meeting of Jianfeng Group's 2016 Annual General Meeting of Shareholders was held in Conference Room 314 of Jianfeng Building to deliberate and pass the "2016 Annual Report on the Work of the Board of Directors" and other proposals. The meeting was convened by the board of directors of Jianfeng Group and chaired by Chairman Jiang Xiaomeng. A total of 6 shareholders and proxies attended the meeting, and the total number of voting shares held by them was 55,604,815, accounting for 16.16 of the total voting shares of the company. Some directors, supervisors and secretary of the board of directors of the company attended the meeting, and some senior managers attended the meeting as nonvoting delegates. The meeting was held and voted on by a combination of on-site voting and online voting, it deliberated and passed nine proposals, including the 2016 Work Report of the Board of Directors, the 2016 Work Report of the Board of Supervisors, the 2016 Financial Final Accounts Report, the 2016 Profit Distribution Proposal, the Proposal to Hire the Company's 2017 Audit Institution, the Proposal to Provide Guarantee to Holding Subsidiaries, the 2016 Annual Report and its Summary, the Election of Mr. Huang Sujian as Director of the Company and the Election of Mr. Chen Tianci as Supervisor of the Company. (Zhou Hengbin)
2020
07-30
Jianfeng Pharmaceutical Won Advanced Collective of Municipal Red Cross Humanitarian Promotion Award
On April 24, the Red Cross Society of Jinhua issued a circular commending the advanced units and individuals of the 2016 Red Cross Humanitarian Promotion Award. Peak Pharmaceutical Company won the Red Cross Humanitarian Promotion Award for Advanced Collective. The Red Cross is a social relief organization engaged in humanitarian work, with the purpose of carrying forward the spirit of humanity, fraternity and dedication, protecting human life and health, and promoting the cause of peace and progress of mankind. As a socially responsible enterprise, Jianfeng Pharmaceutical has always attached importance to public welfare and charity work, vigorously promoted the spirit of the Red Cross, and vigorously supported the work of the Red Cross with practical actions. In September 2016, at the theme publicity activity of "World First Aid Day" and the opening ceremony of the municipal Red Cross emergency rescue station (point), Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, donated 6 AEDs known as "life-saving artifact" to the Red Cross on behalf of Jianfeng Pharmaceutical, it is equipped with six Red Cross emergency rescue service stations (points), namely, Jinhua high-speed railway station, sports center, cultural center, Shuanglong scenic spot, Siping village scenic spot and Suoyuan village scenic spot. The configuration of AED equipment has played a very good role in improving the emergency rescue capacity of Jinhua's key locations, and has been affirmed by the Red Cross and related units. (Spike Pharmaceuticals)
2020
07-31
Jingmai Airport Test Flight Successfully Runway Cement Spike Manufacturing
On April 7, a Boeing 737-700 aircraft of China Eastern Airlines Yunnan took off from Kunming. After completing two flight test subjects, it landed safely at Lancang Jingmai Airport. This not only marked the basic completion of the airport flight area, The official start of the test flight also marked that the "Peak" brand airport runway cement passed the first "final exam". Lancang Jingmai Airport is a major project with milestone significance in the history of Pu'er transportation construction. Since then, an air corridor connecting southwest Yunnan and Southeast Asia has been added between Kunming and Pu'er, which will greatly promote the development and utilization of tourism resources in Lancang, Menglian and Ximeng "Pu'er Green Triangle" area, and promote the sustainable development of local economy and society; it is of great significance to strengthen the city's national defense construction, maintain border stability, promote national unity, improve emergency rescue capabilities, and promote Pu'er's integration into the country's "Belt and Road" construction. Since the start of the construction of the airport, Yunnan Jianfeng has been paying close attention to it, organizing technical research and repeated tests, and finally produced high-quality airport runway special cement, and with excellent product quality, superior product performance and high-quality service, it has become a runway for Lancang Airport. Cement manufacturer. This not only fills the gap of "peak" airport special cement, but also is of great significance to promote the "peak" brand and improve the market influence of enterprises. It is understood that Jingmai Airport is initially confirmed to be officially opened to traffic at the end of May. (Li Liangping)
2020
07-31